Gland Pharma
Ticker >

Gland Pharma share price

Gland Pharma Ltd.

NSE: GLAND BSE: 543245 SECTOR: Pharmaceuticals & Drugs  147k   706   113

1767.80
+18.30 (1.05%)
BSE: 18 Apr 04:01 PM

Price Summary

Today's High

₹ 1775

Today's Low

₹ 1732

52 Week High

₹ 2195.75

52 Week Low

₹ 861.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 29117.53 Cr.

Enterprise Value

₹ 25354.35 Cr.

No. of Shares

16.47 Cr.

P/E

36.35

P/B

3.36

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  526.7

CASH

₹ 3767 Cr.

DEBT

₹ 3.82 Cr.

Promoter Holding

57.86 %

EPS (TTM)

₹  48.64

Sales Growth

-17.82%

ROE

10.28 %

ROCE

13.97%

Profit Growth

-36 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 22 Indices.

NIFTYMIDCAP

NIFTY Midcap 100
48995.7
  -240.948437500003 (-0.489368072658025%)

NIFTYMNC

Nifty MNC
26234.45
  -145.999218749999 (-0.553437197143059%)

NIFTY500

Nifty 500
20324.7
  -98.2999999999993 (-0.481320080301617%)

NIFTYPHARMA

Nifty Pharma
18525.75
  -169.849609375 (-0.908500464942719%)

NIFTYMIDCAP150

Nifty Midcap 150
18195.65
  -64.9496093749985 (-0.355681690439413%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
17153.8
  -40.5496093750007 (-0.235831015980337%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14084.6
  -52.6998046874996 (-0.372771359563484%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
14035.4
  -64.8998046875004 (-0.460272516091642%)

NIFTY200

Nifty 200
12282.7
  -68.7501953124993 (-0.556616382897213%)

NIFTYTOTALMCAP

Nifty Total Market index
11422.95
  -53.2501953124993 (-0.464005458307093%)

NIFTY100ESG

NIFTY100 ESG
4299.6
  -26.7999023437496 (-0.619450419486911%)

MIDCAP

S&P Bse Mid Cap
40159.66
  -155.699999999997 (-0.38620515853014%)

BSE HC

S&P Bse Healthcare
34575.56
  -430.75 (-1.23049244550483%)

BSE500

S&P Bse 500
32097.36
  -172.23 (-0.533722306357165%)

MID150

S&P Bse 150 MidCap
13632.18
  -41.75 (-0.305325535526368%)

MSL400

S&P Bse 400 MidSmallCap
10429.6
  -25.9599999999991 (-0.248288948655062%)

BSE200

S&P Bse 200
10049.61
  -60.2799999999988 (-0.596247832567898%)

LMI250

S&P Bse 250 LargeMidCap
9525.77
  -54.8999999999996 (-0.573028817400034%)

ALLCAP

S&P Bse Allcap
9359.5
  -42.8600000000006 (-0.455843001118872%)

SPBSQIP

S&P Bse Quality
1691.42
  -14.4199999999998 (-0.845331332364108%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
9474.44
  -53.2199999999993 (-0.558584164422316%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
11431.67
  -17.7099999999991 (-0.154680864815382%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-17.82%
3 Year11.16%
5 Year17.42%

Profit Growth

1 Year-36%
3 Year0.13%
5 Year19.29%

ROE%

1 Year10.28%
3 Year16.62%
5 Year18.16%

ROCE %

1 Year13.97%
3 Year22.27%
5 Year24.72%

Debt/Equity

0.0005

Price to Cash Flow

79.15

Interest Cover Ratio

142.408416509307

CFO/PAT (5 Yr. Avg.)

0.629516805150708

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 57.86 0
Dec 2023 57.86 0
Sep 2023 57.86 0
Jun 2023 57.86 0
Mar 2023 57.86 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 22.2746417728597% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 142.408416509307.
  • The Company has been maintaining an effective average operating margins of 34.1868429137207% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 9.43350511298975.
  • The company has a high promoter holding of 57.86%.

 Limitations

  • The company has shown a poor profit growth of 0.127846200154691% for the Past 3 years.
  • The company has shown a poor revenue growth of 11.15610920049% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 925.9 785.42 884.07 1010.67 1097.86
Total Expenditure 641.94 616.27 624.71 663.57 728.37
Operating Profit 283.96 169.15 259.36 347.1 369.49
Other Income 61.51 38.94 35.21 41.11 43.39
Interest 2.62 2.18 1.6 0.91 0.8
Depreciation 37.61 37.54 38.98 40.24 40.33
Exceptional Items 0 -56.46 0 0 0
Profit Before Tax 305.24 111.91 253.99 347.06 371.76
Tax 77.7 32.7 66.41 89.54 94.95
Profit After Tax 227.54 79.21 187.58 257.53 276.81
Adjusted EPS (Rs) 13.82 4.81 11.39 15.64 16.81

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 2044.2 2633.24 3462.88 4400.71 3616.53
Total Expenditure 1337.89 1677.77 2160.61 2890.07 2597.98
Operating Profit 706.31 955.47 1302.27 1510.64 1018.55
Other Income 85.56 139.17 134.78 223.94 240.46
Interest 3.56 7.18 3.41 5.24 7.41
Depreciation 81.96 94.59 98.78 110.3 146.74
Exceptional Items -20 0 0 0 -56.46
Profit Before Tax 686.36 992.87 1334.85 1619.04 1048.4
Tax 234.45 220.01 337.85 406.89 272.58
Net Profit 451.91 772.86 997.01 1212.16 775.83
Adjusted EPS (Rs.) 29.16 49.88 60.95 73.78 47.11

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 15.5 15.5 16.36 16.43 16.47
Total Reserves 2846.62 3630.74 5886.93 7141.8 7936.83
Borrowings 4.96 4.07 3.93 3.82 3.26
Other N/C liabilities 122.83 76.71 76.38 90.15 86.42
Current liabilities 532.68 359.02 512.46 581.94 730.2
Total Liabilities 3522.58 4086.04 6496.06 7834.14 8773.18
Assets
Net Block 928.74 968.1 954.23 1502.19 1570.55
Capital WIP 123.16 188.47 337.81 180.75 177.22
Intangible WIP 0 0 0 10 0
Investments 0 0 0.55 8.16 8.16
Loans & Advances 111.89 81.52 77.97 286.4 128.92
Other N/C Assets 1.33 1.66 2.43 2.21 0
Current Assets 2357.46 2846.29 5123.07 5844.44 6888.34
Total Assets 3522.58 4086.04 6496.06 7834.14 8773.18
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 686.36 992.87 1334.85 1619.04 1048.4
Adjustment 76.12 32.15 17.3 -28.19 37.38
Changes in Assets & Liabilities -353.95 -79.94 -435.8 -393.05 -407
Tax Paid -223.47 -244.14 -311.43 -406.51 -310.89
Operating Cash Flow 185.06 700.94 604.93 791.29 367.89
Investing Cash Flow -318.57 -760.97 -1520.97 -1006.92 1211.22
Financing Cash Flow -2.93 -6.87 1238.46 34.9 14.92
Net Cash Flow -136.44 -66.9 322.42 -180.73 1594.04

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 57.86 57.86 57.86 57.86 57.86
fosun pharma industrial p... 57.86 57.86 57.86 57.86 57.86
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 42.14 42.14 42.14 42.14 42.14
hdfc mutual fund - hdfc m... - - - 2.74 3.08
icici prudential equity &... - - - - 1.22
llp 0.10 0.05 0.05 0.05 0.02
mirae asset large & midca... - - - 5.80 6.19
nicomac machinery private... 1.19 1.19 1.19 1.19 1.19
nippon life india trustee... - - 5.28 5.46 5.53
rp advisory services priv... - - - 3.74 3.74
sbi large & midcap fund - - - 3.13 3.58
uti flexi cap fund 1.43 - 1.24 1.22 1.26
hdfc large and mid cap fu... - - 1.11 - -
icici prudential india op... 4.75 4.14 2.55 - -
mirae asset emerging blue... 4.57 5.08 5.72 - -
r p advisory services pri... 2.61 2.61 2.61 - -
r p advisory services pri... 1.14 1.14 1.14 - -
sbi magnum global fund - 2.47 2.21 - -
aditya birla sun life tru... - 1.08 - - -
nippon life india trustee... - 4.44 - - -
uti flexi cap fund - 1.31 - - -
kotak emerging equity sch... 1.05 - - - -
nippon life india trustee... 3.48 - - - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Company News

Gland Pharma gets USFDA’s approval for Eribulin Mesylate Injection8 Apr 2024, 10:44AM Gland Pharma informs about earnings call transcript21 Feb 2024, 1:07PM Gland Pharma - Quaterly Results14 Feb 2024, 4:19PM Gland Pharma - Quaterly Results14 Feb 2024, 4:19PM Gland Pharma - Quaterly Results14 Feb 2024, 4:19PM Gland Pharma informs about analyst meet18 Jan 2024, 2:25PM Gland Pharma informs about analyst meet7 Dec 2023, 2:50PM Gland Pharma informs about disclosure 24 Nov 2023, 11:29AM Gland Pharma gets EIR for Pashamylaram Facility24 Nov 2023, 10:59AM Gland Pharma informs about analyst meet22 Nov 2023, 3:17PM Gland Pharma informs about press release15 Nov 2023, 2:58PM Gland Pharma gets USFDA’s tentative nod for Angiotensin II Injection15 Nov 2023, 12:25PM Gland Pharma informs about receipt of establishment inspection report from US FDA 8 Nov 2023, 12:38PM Gland Pharma gets EIR for VSEZ Sterile Oncology Facility8 Nov 2023, 12:19PM Gland Pharma informs about press release7 Nov 2023, 1:32PM Gland Pharma - Quaterly Results6 Nov 2023, 4:18PM Gland Pharma - Quaterly Results6 Nov 2023, 4:18PM Gland Pharma - Quaterly Results6 Nov 2023, 4:18PM Gland Pharma informs about disclosure28 Oct 2023, 3:50PM Gland Pharma informs about disclosure28 Oct 2023, 3:44PM Gland Pharma informs about conclusion of US FDA inspection at pashamylaram facility 26 Sep 2023, 4:42PM USFDA concludes inspection at Gland Pharma’s Pashamylaram Facility26 Sep 2023, 12:14PM Gland Pharma informs about analyst meet20 Sep 2023, 2:13PM Gland Pharma informs about analyst meet 20 Sep 2023, 2:05PM USFDA conducts inspection at Gland Pharma’s Pashamylaram Facility in Hyderabad28 Aug 2023, 10:41AM Gland Pharma gets EIR for Dundigal facility24 Aug 2023, 11:52AM Gland Pharma reports 15% fall in Q1 consolidated net profit8 Aug 2023, 12:15PM Gland Pharma - Quaterly Results7 Aug 2023, 4:18PM Gland Pharma - Quaterly Results7 Aug 2023, 4:18PM Gland Pharma - Quaterly Results7 Aug 2023, 4:18PM USFDA concludes GMP inspection at Gland Pharma’s Visakhapatnam facility31 Jul 2023, 2:06PM USFDA concludes GMP inspection at Gland Pharma’s Dundigal facility 14 Jul 2023, 12:58PM Gland Pharma informs about disclosure28 Jun 2023, 5:15PM USFDA concludes PAI, GMP inspection at Gland Pharma’s Pashamylaram facility28 Jun 2023, 11:00AM Gland Pharma informs about analyst meet24 May 2023, 3:37PM Gland Pharma reports 72% fall in Q4 consolidated net profit 19 May 2023, 12:00PM Gland Pharma - Quaterly Results18 May 2023, 5:26PM Gland Pharma - Quaterly Results18 May 2023, 5:26PM Gland Pharma - Quaterly Results18 May 2023, 5:26PM Gland Pharma informs about analyst meet3 May 2023, 4:50PM Gland Pharma informs about analyst meet21 Mar 2023, 12:37PM Gland Pharma submits analyst meet intimation17 Mar 2023, 12:40PM Gland Pharma informs about updates9 Mar 2023, 3:06PM Gland Pharma informs about analyst meet1 Mar 2023, 3:20PM Gland Pharma planning to invest Rs 400 crore to expand Telangana’s existing facility21 Feb 2023, 11:49AM Gland Pharma informs about analyst meet10 Feb 2023, 12:19PM USFDA conducts inspection at Gland Pharma’s API Facility in Visakhapatnam27 Jan 2023, 4:03PM Gland Pharma informs about analyst meet27 Jan 2023, 3:01PM Gland Pharma reports 15% fall in Q3 consolidated net profit24 Jan 2023, 12:17PM Gland Pharma - Quaterly Results23 Jan 2023, 4:12PM

Gland Pharma Stock Price Analysis and Quick Research Report. Is Gland Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Gland Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Gland Pharma cash from the operating activity was Rs 367.893 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Gland Pharma has a Debt to Equity ratio of 0.0005 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Gland Pharma , the EPS growth was -36.1515596345197 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Gland Pharma has OPM of 28.1637249870594 % which is a good sign for profitability.
     
  • ROE: Gland Pharma have a average ROE of 10.2781410489142 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Gland Pharma is Rs 1764.4. One can use valuation calculators of ticker to know if Gland Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Gland Pharma

Gland Pharma Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Gland Pharma Ltd. is a leading pharmaceutical company in India that specializes in the production of injectables. As a long-term stock investor, it is important to analyze the company's financials and performance to make informed investment decisions.  We will discuss various aspects of Gland Pharma Ltd.'s stock analysis page, including its share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Gland Pharma Ltd. Share Price

The share price of Gland Pharma Ltd. is an important factor to consider when analyzing the company's stock. It reflects the market's perception of the company's financial performance and growth prospects. Our pre-built screening tools enable investors to track the company's share price and monitor any fluctuations in real-time.

Gland Pharma Ltd. Balance Sheet

The balance sheet of Gland Pharma Ltd. provides a snapshot of the company's financial position at a specific point in time. It includes assets, liabilities, and equity. Ticker premium features allow for fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools enable investors to analyze the company's financial performance and make informed investment decisions.

Gland Pharma Ltd. Annual Report

The annual report of Gland Pharma Ltd. provides a comprehensive overview of the company's financial performance and operations over the past year. It includes information on the company's revenue, expenses, profits, and losses. Ticker provides downloadable annual reports that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Dividend

Gland Pharma Ltd. has a history of paying dividends to its shareholders. The company's dividend policy reflects its financial performance and growth prospects. Investors can use our pre-built screening tools to track the company's dividend payments and monitor any changes in the dividend policy.

Gland Pharma Ltd. Quarterly Result

The quarterly result of Gland Pharma Ltd. provides information on the company's financial performance and operations over the past quarter. It includes information on the company's revenue, expenses, profits, and losses. Ticker provides downloadable quarterly results that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Stock Price

The stock price of Gland Pharma Ltd. reflects the market's perception of the company's financial performance and growth prospects. Ticker pre-built screening tools enable investors to track the company's stock price and monitor any fluctuations in real-time.

Gland Pharma Ltd. Price Chart

The price chart of Gland Pharma Ltd. provides a visual representation of the company's stock price over a specific period. It enables investors to track the company's stock price trends and make informed investment decisions.

Gland Pharma Ltd. News

Ticker provides the latest news and updates on Gland Pharma Ltd. Investors can use this information to stay up-to-date on the company's performance and make informed investment decisions.

Gland Pharma Ltd. Concall

The concall of Gland Pharma Ltd. provides a platform for the company's management to discuss its financial performance and operations with investors. Ticker provides transcripts of the company's concalls that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Transcripts

Ticker provides transcripts of Gland Pharma Ltd. 's concalls and investor presentations. Investors can use this information to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Investor Presentations

The investor presentations of Gland Pharma Ltd. provide a comprehensive overview of the company's financial performance and operations. Ticker provides downloadable investor presentations that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Promoters

The promoters of Gland Pharma Ltd. are a group of individuals who have a significant stake in the company. They play an important role in the company's management and decision-making processes. Investors can use Ticker pre-built screening tools to track the company's promoters and monitor any changes in their stake.

Gland Pharma Ltd. Shareholders

The shareholders of Gland Pharma Ltd. are individuals or institutions who own a stake in the company. They play an important role in the company's decision-making processes. Investors can use our pre-built screening tools to track the company's shareholders and monitor any changes in their stake.

Read More
X